The innate lymphocyte lineage natural killer (NK) is now the target of multiple clinical applications, although none has received an agreement from any regulatory agency yet. Transplant of naïve NK cells has not proven efficient enough in the vast majority of clinical trials. Hence, new protocols wish to improve their medical use by producing them from stem cells and/or modifying them by genetic engineering. These techniques have given interesting results but these improvements often hide that natural killers are mainly that: natural. We discuss here different ways to take advantage of NK physiology to improve their clinical activity without the need of additional modifications except for in vitro activation and expansion and allograft in patients. Some of these tactics include combination with monoclonal antibodies (mAb), drugs that change metabolism and engraftment of specific NK subsets with particular activity. Finally, we propose to use specific NK cell subsets found in certain patients that show increase activity against a specific disease, including the use of NK cells derived from patients.
Keywords: CD45RARO; NK cells; antibody-dependent cell cytotoxicity (ADCC); autoimmune diseases; microenvironment; monoclonal antibodies (mAbs).
Copyright © 2020 Villalba, Alexia, Bellin-Robert, Fayd'herbe de Maudave and Gitenay.
Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors.Theranostics. 2018 Jun 14;8(14):3856-3869. doi: 10.7150/thno.25149. eCollection 2018. Theranostics. 2018. PMID: 30083264 Free PMC article.
Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.Exp Hematol. 1999 Oct;27(10):1533-41. doi: 10.1016/s0301-472x(99)00089-2. Exp Hematol. 1999. PMID: 10517495
Combination immune therapies to enhance anti-tumor responses by NK cells.Front Immunol. 2013 Dec 23;4:481. doi: 10.3389/fimmu.2013.00481. Front Immunol. 2013. PMID: 24391651 Free PMC article.
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.Ann Transl Med. 2019 Mar;7(5):105. doi: 10.21037/atm.2019.01.42. Ann Transl Med. 2019. PMID: 31019955 Free PMC article. Review.
Translating the anti-myeloma activity of Natural Killer cells into clinical application.Cancer Treat Rev. 2018 Nov;70:255-264. doi: 10.1016/j.ctrv.2018.10.005. Epub 2018 Oct 10. Cancer Treat Rev. 2018. PMID: 30326421 Review.